39830-63-2 Usage
Uses
Used in Pharmaceutical Industry:
3-Hydroxy-4-nitroisoindolin-1-one is used as a building block for the synthesis of pharmaceuticals due to its highly reactive and versatile chemical structure.
Used in Dye Industry:
3-Hydroxy-4-nitroisoindolin-1-one is used as a building block for the synthesis of dyes due to its chemical properties.
Used in Organic Synthesis:
3-Hydroxy-4-nitroisoindolin-1-one is used as a reagent in organic synthesis for the production of various organic compounds.
Used in Medicinal Chemistry and Drug Discovery:
3-Hydroxy-4-nitroisoindolin-1-one is used in the field of medicinal chemistry and drug discovery due to its potential antimicrobial and anticancer properties.
Check Digit Verification of cas no
The CAS Registry Mumber 39830-63-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,9,8,3 and 0 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 39830-63:
(7*3)+(6*9)+(5*8)+(4*3)+(3*0)+(2*6)+(1*3)=142
142 % 10 = 2
So 39830-63-2 is a valid CAS Registry Number.
39830-63-2Relevant academic research and scientific papers
PI3K-α INHIBITORS AND METHODS OF USE THEREOF
-
Paragraph 0890, (2021/11/06)
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of PI3K-α enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is n
HPK1 ANTAGONISTS AND USES THEREOF
-
Paragraph 1338; 1339, (2021/03/19)
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
ROCK KINASE INHIBITORS
-
Paragraph 0223-0225, (2020/05/29)
The present invention relates to compounds that inhibit ROCK activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of inhibiting ROCK activity and methods for treating, for example cerebral cavernous malformation syndrome (CCM) and cardiovascular diseases using the compounds and pharmaceutical compositions of the present invention.
